Lack of funding threatens the future of HIV drug therapy in the developing world

Ten years ago, many experts thought you couldn't bring antiretroviral therapy to people with AIDS in poor countries. The drugs cost too much, there weren't enough doctors, the patients wouldn't take the medicines correctly, and the risk of creating a resistant virus was too high. HIV - AIDS - Health - Conditions and Diseases - Immune Disorders

Security Suites: Big Protection, Little Fuss

Just a few short years ago, all a PC needed for protection was a basic antivirus program to guard against any malware that arrived via an e-mail attachment... antivirus - Malware - Security - Personal computer - Malicious Software

McAfee, Inc. Reports Results for the Second Quarter of 2010

SANTA CLARA, Calif.----McAfee, Inc. today reported financial results for the second quarter ended June 30, 2010.

No use burying head in the sand on AIDS

AFTER nearly three decades of the HIV pandemic and more than 33 million infections worldwide, more than 19,000 participants at the 18th international AIDS conference in Vienna last week were re-energised with some good news and new hopes in the search for effective prevention and treatment strategies.

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck today announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.